Global PRMT 5 Inhibitors Market Companies
- laxoSmithKline Plc.
- Janssen
- Merck
- Mirati Therapeutics Inc.
Recent News:
- According to PubMed Central article, Protein arginine methyltransferase 5 (PRMT5) inhibitors are a new class of antineoplastic agents showing promising preliminary clinical efficacy. Targeting an enzyme involved in a wide array of cellular and transcriptional pro-oncogenic processes, this class offers multifaceted tumor-suppressive effects.